ArticleFrontiers in pain research (Lausanne, Switzerland)2026
Case Report: Intravenous fosphenytoin successfully treated acute exacerbation of secondary trigeminal neuralgia due to petroclival meningioma.
Article in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Trigeminal neuralgia (TN) is a severe paroxysmal neuropathic pain disorder. While various strategies have been proposed for managing acute exacerbations of classical TN, treatment approaches for secondary TN remain largely undocumented. Here, to the best of our knowledge, we present the first reported case of secondary TN crisis due to a petroclival meningioma, successfully managed with intravenous fosphenytoin. Case description: A 62-year-old woman developed right-sided TN secondary to a petroclival meningioma. Her facial pain resolved after tumor resection but recurred six years later with slight tumor regrowth. Despite escalation of carbamazepine (CBZ) and CyberKnife radiosurgery, she experienced a TN crisis, presenting with persistent severe pain and impaired oral intake. Intravenous fosphenytoin was administered at loading dose over 20 min, resulting in nearly complete pain relief. Because of symptom recurrence, fosphenytoin was continued at maintenance dose for seven days, in parallel with CBZ titration to 800 mg/day and addition of baclofen. Oral intake improved rapidly thereafter, and no further acute exacerbations were observed over three months of follow-up. Conclusion: This case highlights the potential of intravenous fosphenytoin as an effective and rapid treatment for acute crisis of secondary TN, especially when oral therapy is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.